CRNX Relative Valuation
CRNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRNX is overvalued; if below, it's undervalued.
Historical Valuation
Crinetics Pharmaceuticals Inc (CRNX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 261.07 is considered Undervalued compared with the five-year average of -8.04. The fair price of Crinetics Pharmaceuticals Inc (CRNX) is between 42.75 to 374.12 according to relative valuation methord. Compared to the current price of 31.19 USD , Crinetics Pharmaceuticals Inc is Undervalued By 27.03%.
Relative Value
Fair Zone
42.75-374.12
Current Price：31.19
27.03%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.38
P/B
Median3y
3.80
Median5y
3.62
-8.90
FCF Yield
Median3y
-8.59
Median5y
-9.23
Competitors Valuation Multiple
The average P/S ratio for CRNX's competitors is 58.55, providing a benchmark for relative valuation. Crinetics Pharmaceuticals Inc Corp (CRNX) exhibits a P/S ratio of 261.07, which is 345.91% above the industry average. Given its robust revenue growth of -43.59%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Crinetics Pharmaceuticals Inc (CRNX) currently overvalued or undervalued?
What is Crinetics Pharmaceuticals Inc (CRNX) fair value?
How does CRNX's valuation metrics compare to the industry average?
What is the current P/B ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Jul 19 2025?
What is the current FCF Yield for Crinetics Pharmaceuticals Inc (CRNX) as of Jul 19 2025?
What is the current Forward P/E ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Jul 19 2025?